Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors
ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to…